The patient study is now fully recruited

Chordate Medical estimates that a sufficient number of patients have been recruited for the study on migraine which is being carried out in Germany and Finland - and that the number of patients prescribed by the study design has thus been met.

The main purpose of the patient study, which began in 2018, was from the beginning to enable a CE marking of the company's preventive treatment of chronic migraine. Since Chordate already in May 2021 received the CE marking on interim data from the same study, the main purpose was fulfilled, however, a positive result from the patient study is still extremely important for the continued marketing activities. The goal is to get a scientific article published. The article is expected to be completed and submitted for scientific review no earlier than the end of the third quarter of 2022, as the last patient will now leave the study in July.

"An article in a scientific journal will support our market positioning and our sales work in all selected markets, including countries outside the EU", says Anders Weilandt, CEO of Chordate.

The international patient study on the patented treatment method K.O.S against chronic migraine began in 2018. The study, which is carried out at nine clinics in Germany and Finland, was paused due to the covid-19 pandemic in 2020 but resumed intermittently in 2021 when the pandemic progression allowed.

For more information, please contact:
Anders Weilandt, CEO
[email protected]
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com.
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, [email protected].

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Subgruppsresultat från Chordates kliniska studie PM007 presenteras på migrän-symposium i London

Chordate Medical Holding AB (publ) ("Chordate") (Nasdaq First North Stockholm: CMH) tillkännager idag att ett abstract med titeln "Kinetic Oscillation Stimulation for the treatment of chronic migraine - a subgroup analysis of a randomised controlled clinical trial" av Hoffmann, J. et al, kommer presenteras på Migraine Trust International Symposium 2022 [MTIS], 8-11 september 2022, i London.


Subgroup results from Chordates PM007 multicenter clinical study of K.O.S-stimulation will be presented at Migraine symposium in London

Chordate Medical Holding ABs (publ) ("Chordate") (Nasdaq First North Stockholm: CMH), a specialty medtech company that focuses on developing neuromodulating systems for treating chronic migraine, today announces that an abstract entitled "Kinetic Oscillation Stimulation for the treatment of chronic migraine - a subgroup analysis of a randomised controlled clinical trial" by Hoffmann, J. et al, has been accepted as a poster by the Migraine Trust International Symposium 2022 [MTIS], September 8-11, 2022, London.


Chordate Medical har fått besked om beviljande av ytterligare patentskydd för huvudvärksbehandling i USA

Chordate Medical Holding AB (Publ.) meddelar att det amerikanska patentverket har utfärdat ett beslut om att de avser bevilja Chordates patentansökan US 16/938,383 från 2020. 


Chordate Medical has been notified of the granting of additional patent protection for headache treatment in the United States

Chordate Medical Holding AB (Publ.) announces that the US Patent Office has issued a decision that they intend to grant Chordates patent application US 16 / 938,383 from 2020. 


Chordate Medical uppdaterar om pågående och planerade kliniska studier

Chordate Medical har för tillfället två aktiva studier, och ytterligare två som är i planeringsstadiet. Syftet med bolagets kliniska utvecklingsprogram är att stödja den pågående marknadsintroduktionen av K.O.S-teknologin för kronisk migrän i EU och lägga grunden för regulatoriskt marknadstillträde på andra marknader såsom USA.

- Vår kliniska utvecklingsstrategi syftar till att själva genomföra studier av specifik karaktär och kortare varaktighet, och att uppmuntra och underlätta andra oberoende och externt initierade studier när sådana möjligheter uppstår, säger Anders Weilandt, vd Chordate.


Chordate Medical updates on ongoing and planned clinical studies

Chordate Medical has two active studies, and another two that are in the planning stage. The purpose of the company's clinical development program is to support the ongoing market introduction of the K.O.S technology for chronic migraine in the EU and lay the foundation for regulatory market access in other markets such as the USA.

"Our clinical development strategy is aimed to conduct studies of specific nature and shorter duration ourselves, and to encourage and facilitate other independent external investigator-initiated studies once such opportunities arise", says Anders Weilandt, CEO Chordate.




Chordate Medical presenterar delårsrapport för Q1 2022

Chordate Medical Holding (publ) offentliggör sin delårsrapport för Q1 2022 fredagen den 27 maj 2022 klockan 08:30. Måndag den 30 maj klockan 14:00 bjuder bolaget in till en webbsänd telekonferens med vd Anders Weilandt. Efter konferensen följer en frågestund. Det går att följa konferensen via dator eller mobila enheter.


Chordate Medical presents interim report for Q1 2022

Chordate Medical Holding (publ) publishes its interim report for Q1 2022 on Friday, May 27th, 2022, at 08:30. On Monday, May 30th at 14:00, the company invites the public to a livestreamed teleconference with CEO Anders Weilandt. The conference is followed by a Q&A session. You can follow the conference via computer or mobile devices.


Chordate Medicals vd Anders Weilandt presenterar på BioStock Life Science Spring Summit 8 juni

Chordate Medicals vd Anders Weilandt deltar på BioStock Life Science Spring Summit 8 juni, klockan 11:20. Han kommer presentera de senaste händelserna och utvecklingarna i bolaget, såsom den nyligen avklarade första fasen i ansökan om marknadstillstånd för K.O.S-behandlingen i USA, det kommande representationskontoret i Saudiarabien och marknadsinsatserna i Storbritannien.


CEO Anders Weilandt presents Chordate Medical at BioStock Life Science Spring Summit on June 8th

Chordate Medical's CEO Anders Weilandt will participate on BioStock Life Science Spring Summit on June 8th, at 11:20. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.


Chordate Medicals vd Anders Weilandt deltar på investerarkonferens 9 juni

Torsdag 9 juni klockan 14.10 deltar Chordate Medicals vd Anders Weilandt på en investerarkonferens som anordnas av Västra Hamnen Corporate Finance i samarbete med Nordnet. Han kommer presentera de senaste händelserna och utvecklingarna i bolaget, såsom den nyligen avklarade första fasen i ansökan om marknadstillstånd för K.O.S-behandlingen i USA, det kommande representationskontoret i Saudiarabien och marknadsinsatserna i Storbritannien.


CEO Anders Weilandt presents Chordate Medical at Investment event on June 9th

On Thursday, June 9th, 14:10 CET, Chordates CEO Anders Weilandt will participate on an investment event hosted by Västra Hamnen Corporate Finance. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.


Kommuniké från årsstämma i Chordate Medical (publ)

Chordate Medical Holding AB (Publ) ("Chordate" eller "Bolaget") har den 25 april 2022 hållit årsstämma, varvid följande huvudsakliga beslut, i enlighet med kallelsens förslag, fattades.


Patientstudien nu färdigrekryterad

Chordate Medical bedömer att tillräckligt många patienter rekryterats till studien om migrän som genomförs i Tyskland och Finland - och att patientantalet som studiedesignen föreskriver därmed är uppfyllt.


The patient study is now fully recruited

Chordate Medical estimates that a sufficient number of patients have been recruited for the study on migraine which is being carried out in Germany and Finland - and that the number of patients prescribed by the study design has thus been met.


Chordate Medicals vd Anders Weilandt presenterar på Aktiedagen 2 maj

Måndag 2 maj klockan 11.00 deltar Chordates vd Anders Weilandt på Aktiedagen Stockholm. Han kommer presentera de senaste händelserna och utvecklingarna i bolaget, såsom den nyligen avklarade första fasen i ansökan om marknadstillstånd för K.O.S-behandlingen i USA, det kommande representationskontoret i Saudiarabien och marknadsinsatserna i Storbritannien.


CEO Anders Weilandt presents Chordate Medical at Aktiedagen on May 2nd

On Monday 2 May, 11:00, Chordate's CEO Anders Weilandt will participate on Aktiespararnas event Aktiedagen Stockholm. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted